Standard Service …
Names are screened for obvious sound-alike and look-alike similar drug names using specific databases per scope of work that usually include US (drugs@FDA), Europe (Article 57), and Canada (drug product database).
Names are screened for potential promotional considerations regarding overly fanciful claims.
PLUS Services …
POCA Screening during the Creative Phase includes the name candidates will be screened using the FDA’s POCA Tool (Combined Similarity Threshold of 70%). When used during the creative process, the output from the POCA tool is provided to the creative agency and ultimately used to help re-craft name candidates.
Word Construction Analysis considers name similarity “beyond POCA” when reviewing cited name pairs for potential conflicts based on word construction (starting letter, prefix, suffix, number of characters, etc.).
Percent Derivation is a tool that compares the letters/letter string of the nonproprietary name with the proposed brand name which may lead to confusion in practice among healthcare professionals.
SRC Stem Check is where each name candidate will be screened for USAN and/or INN stems and the evaluation includes whether the brand name appears to be derived from the nonproprietary name and whether the brand name may be confused with a common name.
Remember SafeMark does not create brand names so we work with agencies that create names or pharmaceutical clients that have a list of names that are ready for our prescreening services!
All PLUS PRESCREENING SERVICES are included in the Power of 3 Methodology.